A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

87 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this trial is to estimate and compare the 12-week progression-free rate of BIBF 1120, BIBW 2992 or sequential administration of BIBF 1120 and BIBW 2992 in patients with HRPC as determined by radiographic, bone and PSA criteria.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer

NCT02182063

Prostatic Neoplasms

COMPLETED PHASE2

Phase II Study of BI 2536 in Prostate Cancer

NCT00706498

Prostatic Neoplasms

COMPLETED PHASE2

Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer

NCT02182219

Prostatic Neoplasms

COMPLETED PHASE1

Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency

NCT03712930

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Homologous Recombination Deficiency (HRD)

TERMINATED PHASE2

Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

NCT00486642

Hormone-Resistant Prostate Cancer Recurrent Prostate Carcinoma

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostatic Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BIBF 1120

Intervention Type DRUG

BIBW 2992

Intervention Type DRUG

Sequential BIBF 1120 + BIBW 2992

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \>18 years.
* Signed informed consent.
* Able to comply with protocol requirements.
* Histologically, cytologically or biochemically documented adenocarcinoma of the prostate, clinically refractory or resistant to hormone therapy, as documented by progression following at least one hormonal therapy, which must include orchidectomy or gonadotropin releasing hormone agonist (GnRHa).
* Progressive Disease (PD) is defined as a minimum of three consecutive serum PSA measurements obtained at least 7 days apart within the previous 3 months of start of trial, which document progressively increasing values. Patients with progression of measurable disease (RECIST) or progression of bone disease must also fit the criterion for PSA progression.
* Patients must have documented progression (as defined above) following anti-androgen withdrawal of 4 weeks duration for flutamide and 6 weeks for bicalutamide or nilutamide. For a patient who has withdrawn from anti-androgen therapy less than 6 months prior to inclusion in trial one of the following criteria is also required:
* Following the completion of the anti-androgen withdrawal period one PSA higher than the last pre-withdrawal PSA.
* Or Following the completion of the anti-androgen withdrawal period if the PSA value has decreased, he can still qualify if 2 increases in PSA are documented after the post- withdrawal nadir.
* PSA \> 5ng/mL.
* Life expectancy of at least 12 weeks.
* ECOG performance status 0-1 (see appendix 11.2).
* Stable analgesia requirements.
* Adequate hepatic function: total bilirubin \< 26µmol/L, ALT and/or AST \< 1.5x upper limit of normal (ULN).
* Adequate renal function: serum creatinine \< 1.5 x ULN.
* INR Prothrombin time (PT) and partial thromboplastin time (PTT) \<1.5 upper limit of normal.
* Absolute neutrophil count (ANC) \> 1.5 x 109l, Platelets \> 100 x 109/l.
* Haemoglobin \> 9.0 g/dl.
* LVEF \> 50 % on MUGA scan or echocardiogram.
* Castrate testosterone level \[\< 20ng/dl or \<0.69nM (nM/L x 28.8 = ng/dl)\], which must be maintained during the duration of the trial by orchidectomy or medical castration.
* Patient on oral or intravenous bisphosphonates are allowed to enter the trial as long as they have been on bisphosphonates for a minimum of 3 months.

Exclusion Criteria

* Prior treatment with inhibitors of EGFR, HER 2 and/or VEGF receptors.
* Prior treatment with cytotoxic chemotherapy.
* Known hypersensitivity to the trial drugs or their excipients.
* Systemic corticosteroids 28 days before screening (inhaled corticosteroids prescribed for bronchospasm are allowed). Patients on long-term stable-dose steroids for concurrent illness are not excluded.
* Treatment with any investigational drug within 28 days of trial onset.
* History of other malignancies which could affect compliance with the protocol or interpretation of results within 5-years. Patients with adequately treated basal or squamous cell skin cancer are generally eligible.
* Serious illness or concomitant non-oncological disease such as neurologic, psychiatric, infectious disease or active ulcers (gastro-intestinal tract, skin) or laboratory abnormality that may increase the risk associated with trial participation or trial drug administration and in the judgment of the investigator would make the patient inappropriate for entry into the trial.
* Major injuries and/or surgery within 4 weeks of trial onset or bone fracture and planned surgical procedures during the trial period.
* Significant cardiovascular diseases (i.e. uncontrolled hypertension, unstable angina, history of infarction within past 9 months, congestive heart failure \> NYHA II) (see appendix 11.5).
* History of haemorrhagic or thrombotic event in the past 12 months. Known inherited predisposition to bleeds or to thrombosis.
* Patient with history or clinical evidence of CNS disease or brain metastases.
* Patients with symptoms of impending or established spinal cord compression.
* Gastrointestinal disorders or abnormalities that would inhibit absorption of the trial drug.
* Patients who require full-dose anticoagulation.
* Radio- or immunotherapy within the past four weeks prior to treatment with the trial drug.
* Patients unable to comply with the protocol.
* Active alcohol or drug abuse.

Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No